fenofibrate and triazoles

fenofibrate has been researched along with triazoles in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (57.14)	29.6817
2010's	3 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jung, M; Schemies, J; Sippl, W	1
Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K	1
Gonzalez, FJ; Hossain, MA; Tsujita, M; Yokoyama, S	1
Akita, N; Fukutomi, T; Gonzalez, FJ; Hossain, MA; Kimura, G; Ogata, M; Staels, B; Suzuki, S; Tsujita, M; Yokoyama, S	1
Chew, GT; Sahebkar, A; Watts, GF	1
Nie, J; Wang, F; Wang, H; Zhang, C	1
Hirschfield, GM; Webb, GJ	1

Reviews

4 review(s) available for fenofibrate and triazoles

Article	Year
Histone deacetylase inhibitors that target tubulin. Cancer letters, 2009, Aug-08, Volume: 280, Issue:2 Topics: Acetylation; Binding Sites; Epigenesis, Genetic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Isoxazoles; Models, Molecular; Naphthalenes; Protein Binding; Pyrones; Sirtuin 2; Sirtuins; Triazoles; Tubulin; Tubulin Modulators	2009
New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:4 Topics: Acetates; Animals; Atherosclerosis; Chalcones; Cholesterol, HDL; Dyslipidemias; Fatty Liver; Fenofibrate; Humans; Insulin Resistance; Lipoproteins, HDL; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Propionates; Quinolines; Sulfonamides; Thiazoles; Triazoles; Triglycerides	2014
Protective factors in diabetic retinopathy: focus on blood-retinal barrier. Discovery medicine, 2014, Volume: 18, Issue:98 Topics: Animals; Blood-Retinal Barrier; Diabetic Retinopathy; Erythropoietin; Fenofibrate; Humans; Insulin-Like Growth Factor Binding Protein 3; Macular Edema; Protective Factors; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Endothelial Growth Factor A	2014
Work in Progress: Drugs in Development. Clinics in liver disease, 2018, Volume: 22, Issue:3 Topics: Abatacept; Acetates; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Bezafibrate; CD40 Antigens; CD40 Ligand; Chalcones; Chemokine CX3CL1; Chenodeoxycholic Acid; Cholic Acids; Drug Development; Fenofibrate; Fibroblast Growth Factors; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Janus Kinase Inhibitors; Liver Cirrhosis, Biliary; Methylamines; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Propionates; Pruritus; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Thiazepines; Triazoles; Ustekinumab	2018

Trials

1 trial(s) available for fenofibrate and triazoles

Article	Year
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA, 2007, Mar-28, Volume: 297, Issue:12 Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles	2007

Article

Year

Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.

JAMA, 2007, Mar-28, Volume: 297, Issue:12

Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles

2007

Other Studies

2 other study(ies) available for fenofibrate and triazoles

Article	Year
Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:3 Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blotting, Western; Cells, Cultured; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Hepatocytes; Hypolipidemic Agents; Lipoproteins, HDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Propionates; Triazoles	2008
On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis, 2009, Volume: 205, Issue:2 Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles	2009

Article

Year

Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.

Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:3

Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Blotting, Western; Cells, Cultured; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Hepatocytes; Hypolipidemic Agents; Lipoproteins, HDL; Mice; Mice, Inbred C57BL; Mice, Knockout; Peroxisome Proliferator-Activated Receptors; Propionates; Triazoles

2008

On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

Atherosclerosis, 2009, Volume: 205, Issue:2

Topics: Animals; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bezafibrate; Cell Line, Tumor; Fenofibrate; Fibroblasts; Gemfibrozil; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pioglitazone; PPAR delta; PPAR gamma; Propionates; Thiazoles; Thiazolidinediones; Triazoles

2009